The International Pharmaceutical Congress Advisory Association (IPCAA) aims to enhance medical congress outcomes through consistent policies and partnerships, responding to a changing landscape of tightened budgets and increased scrutiny. Established in 1989, it represents healthcare industry interests and facilitates discussions on compliance and transparency in medical congresses. Recent trends indicate a shift towards scientific engagement, reduced industry support for healthcare professionals, and increased geographical and cost considerations in congress planning.

1. HOST
SPONSORS
#ACIE15 ORGANISED BY
Co-President
COMPLIANCE: The Corporate Perspective
CHRISTIAN-CLAUS ROTH
International Pharmaceutical Congress
Advisory Association
© Associations Network 2015

2. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Christian-C. Roth
IPCAA Co-President
Head Global Event Governance – Novartis Pharma AG
Compliance – the Corporate Perspective
2

3. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
An Overview
The International Pharmaceutical
Congress Advisory Association
IPCAA

4. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
IPCAA mission statement
"To ensure the most beneficial outcome for
all parties involved in medical congresses,
through the development of
common and consistent congress policies and through
recognised partnerships with medical societies."

5. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
History
• Formed in 1989 as the European Pharmaceutical Congress
Advisory Association (EPCAA), in 1991 change into International
Pharmaceutical Congress Advisory Association (IPCAA)
• First active members were Astra, Bayer, Ciba-Geigy, Glaxo,
Hoechst, ICI, Janssen, Organon, Roche, Sandoz, Schering and
SmithKline Beecham
Reasons for formation:
• „mushrooming“ of congresses
• new and emerging regulations
• sponsor contracts
Note - The IPCAA and its members are aware of competition and anti-trust aspects.
Vigilance is exercised, to avoid any discussion of topics that could raise anti-trust concerns.

6. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
IPCAA objectives
• Act and be regarded as the voice of healthcare industry with leading
policy-making healthcare organisations internationally
• Facilitate and organise platforms for discussion of topics amongst
relevant meetings industry stakeholders to contribute to improve
understanding of congress-related issues such as compliance and
transparency
• Continue to offer high level education and information exchange in
congress related matters.
• Partner with medical societies and congress organisers on innovation, e.g.
new technologies to enhance medical education dissemination of high level
science.
• Facilitate interactions within industry in order to play an instrumental role
to determine the future of congress formats, policies etc.

7. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Why are we doing all of this?

8. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Changing Landscape
Changing landscape with
• tightened budgets
• rising costs of healthcare
• public scrutiny
• reinforcement of laws and codices (FCPA, UK Bribery Act)
• industry‟s reputational challenges
• lack of transparency
have led to a significant review of certain activities
General financial situation in many countries has triggered a new
view on well known practices

9. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Changing Landscape in the
medical congress world
• Over the last couple of years a strong review and implementation of
compliance programs within the Industry
• Extension of scope and reach of various codes (“crossboarder”)
• Multi layer approach, take into consideration
-where company is based
-where it operates and
-with whom it interacts
What used to be a logistical task developed into a complex
challenge requiring a different approach and skill set

11. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Laws
 International
Reach
(e.g. FCPA,
UK Bribery
Act)
 International
(e.g. IFPMA,
EFPIA)
 National  National
Self Regulation
(Industry Codes)
Company
regulations
Might impose
more stringent
requirements

12. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
• International Federation of Pharmaceutical Manufacturers &
Associations
• Represents the research-based pharmaceutical industry and the
biotechnology and vaccine sectors
• Scope of the 2012 revision of the IFPMA Code has expanded beyond
marketing practices to cover interactions with healthcare
professionals, medical institutions and patient organizations.
• Launched in March 2015 the «Note for Guidance on Sponsorship of
Events and Meetings»
IFPMA

13. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
• European Federation of Pharmaceutical Industries and Associatiosn
• EFPIA represents the pharmaceutical industry operating in Europe,
direct membership 33 national associations and 38 leading
companies (plus Vaccines Europe), with 9 member companies and
emerging bio-pharmaceutical companies – EBE with approx. 65
member companies.)
• EFPIA‟s members are bound by a code of practice governing these
exchanges with those who prescribe, dispense and use medicines.
• e4ethics Assessment Platform
• EFPIA Disclosure Code launched in 2014, Data Collection in 2015,
Reporting of HCP and HCP Spend in 2016. 33 Different Reporting
requirements.
EFPIA

14. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
The local Codes and regulations
• Significant increase of local codes and regulations based on
IFPMA and EFPIA standards with additional national requirements
• Constant changes and interpretation standards
• Local mandatory review or approval bodies (e.g
Mdeon, Farmaindustria)
• At the end every company must interpret external codes, set own
standards and roll out their own compliance program

15. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Medical Congresses
• Pharmaceuticals Industry Focus is on Scientific, Medical Education
• Main Focus at a congress is on the Scientific Program and the
Symposia - Scientific Education & Exchange
• Congress Exhibition is a mixture of commercial and medical
activities which should be distinct. These two areas of activities
require different review and approval forms.
• Two different and distinct levels:
• Company Activities at congress - e.g exhibition, symposia
• Support of HCPs to attend

16. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Key Stakeholders to consider...
Medical
Congress /
Medical
Associaton
CME Provider
Medical
Society / PCO
Delegations Origin
& HCP in general
IFPMA
EFPIA
e4ethics
Suppliers / 3rd
parties
Speakers /
Experts
Company
Standards
Host Country
Regulations
EUCOMED et
al

17. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
What should be done?
• Collaboration internally with Congress Managers & Logistics Function
• Collaboration of all involved internal & external parties. Use Industry Bodies
like IPCAA Forums to address common issues and raise awareness and
provide training
• «Destination» is part of the Industry‟s assessment, very often the
reputational aspect is a key criteria, how the destination and infrastructure is
positioned. Raise awareness!
• Co-promotion partner could influence the perception. Avoid that touristical
attractiveness overshadows the business view. Address this with Congress
Organizer and third party suppliers.
• Infrastructure criteria, security considerations and access from countries &
continents in relation to the event must be given. Share this with Organizer
• Understand that «social part» of a congress can create huge issues for
Pharma Companies.

18. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
What should be done?
• Certain words (e.g. Gala Dinner) and activities (e.g. shows of local
culture) are not in line with Industry's standards, they should not be
proposed
• Focus on “science” results in increase need for symposia
halls, poster areas and meeting rooms etc. The exhibition part is
decreasing. The selection of a destination or center must be due to
the respective infrastructure, not the attractiveness.
• Be aware that many Compliance Officers are searching the Internet
for «publicly available information», if the destination and congress
is promoted as touristic overall this could be challenging.

19. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
What should be done?
• Understand that there might different interpretations of codes or
regional differences (e.g. «Middle Eastern Medical Congress of
XYW» in Dubai might allow different activities as the «International
Medical Congress of ABC» in Dubai)
• Medical Societies can arrange congresses and meetings up to their
own standards, the support of Pharma Industry or the support of
delegates to attend might not be possible. Lets work together.
• Ensure that all company affiliates and regions are trained to the
same standards. Raise awareness that Country delegations and
HCP support are in focus, if not done right huge risk

20. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
“Please note that the following slides „Trends and Outlook‟ are the
personal opinion of the speaker basing on his observation and
experience as professional and IPCAA Co-President. Since they look
into the future, no certain outcome can be guaranteed.”

21. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
Potential Trends and Outlook –
to name a few...
• Pharmaceutical Companies will act differently on the mentioned
codes
• Less direct Industry support to HCPs, Shift to co-payment
arrangements
• Shift from Marketing to Science - new and different ways of
supporting scientific interactions
• Increased geographical reach. LatCan and AsiaPac will come more
into consideration
• Prices & cost will become a new criteria in public reporting
• New generation & expectations to have access to information at any
time, everywhere and for free...
• Increased awareness of Environmental issues

22. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S

23. E X C E L L E N C E I N G L O B A L H E A L T H C A R E C O N G R E S S E S
www.associationscongress.com
www.associationsnetwork.org